JB/CALL/MODERNA/150/0.0333/21.03.25 | Market Closed - Swiss Exchange 11:20:00 2024-07-12 am EDT | ||
| 0.53 CHF | +3.92% |
|
| Current month | +15.22% | ||
| 1 month | -40.45% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-07-12 | 0.53 | +3.92% |
| 24-07-11 | 0.51 | +15.91% |
| 24-07-10 | 0.44 | +2.33% |
| 24-07-05 | 0.43 | +2.38% |
| 24-07-02 | 0.42 | -4.55% |
Delayed Quote Swiss Exchange
Last update July 12, 2024 at 11:20 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | MODERNA, INC. |
| Issuer | Bank Julius Bär |
| MRNGJB | |
| ISIN | CH1317198294 |
| Date issued | 2024-01-11 |
| Strike | 150 $ |
| Maturity | 2025-03-21 (252 Days) |
| Parity | 30 : 1 |
| Emission price | 0.5 CHF |
| Emission volume | N/A |
| Settlement | cash |
| Currency | CHF |
Technical Indicators
| Highest since issue | 1.37 CHF |
|---|---|
| Lowest since issue | 0.2 CHF |
| Spread | 0.01 CHF |
| Spread % | 1.85% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
122.8
USD
Average target price
145.9
USD
Spread / Average Target
+18.79%
- Stock Market
- Warrants
- MRNGJB Warrant
